Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD
Upcoming SlideShare
Loading in...5
×
 

Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD

on

  • 727 views

Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia. ...

Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.

Dr. Luc Truyen, MD, PhD, VP Neuroscience External Affairs and Chair, Johnson&Johnson, Global Fight against !lzheimer’s Disease

Statistics

Views

Total Views
727
Views on SlideShare
152
Embed Views
575

Actions

Likes
0
Downloads
3
Comments
0

2 Embeds 575

http://dementiachallenge.dh.gov.uk 570
https://dementiachallenge.dh.gov.uk 5

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD Presentation Transcript

  • Brian Jackson, Untitled 6 Artwork from Reflections Art in Health I have been impressed with the urgency of doing. Knowing is not enough; we must apply. Being willing is not enough; we must do. –Leonardo da Vinci Luc Truyen MD PhD VP Neuroscience External Affairs Janssen and Chair, Global Fight against Alzheimer’s Disease, Johnson & Johnson Program Director, Global Alzheimer’s Platform Global Collaboration: key to conquering Alzheimer’s Disease
  • Disclaimer The opinions expressed in this presentation are those of the presenter only and do not necessarily reflect the positions or opinions of Janssen Research and Development, L.L.C. or any other individual or affiliate of Johnson & Johnson. The presenter makes no warranties with respect to the accuracy of the data or materials presented herein. All information is provided for informational purposes only and does not constitute advice regarding clinical research-related activities.
  • Photograph by Judith Fox from I Still Do: Loving and Living with Alzheimer's We need to change the dialogue: From the 70 year old patient with Alzheimer’s Dementia To the 40 year old person with Alzheimer’s Disease
  • Key needs to get to ‘disease interception’  Increased investment in basic science  Incentivized innovators  Identifying and capturing the right subjects for trials – Clinimetrics – Diagnostics and Biomarkers – ‘Registries’  Translational infrastructure – Registries to trial ready cohorts – Sites that are qualified and ready with access to required tech – Effective trial designs: learn fast, confirm efficiently  Relevant outcomes – Surrogate markers – Sensitive cognitive measures – Economic impact models  A convergent, synchronized regulatory and payor environment
  • Global Alzheimer’s Platform U.K. Dementia Platform AIBL COLLABORATION DATA SHARING KNOW HOW AMP WW-ADNI We need a global connectome
  • Thank you